LIVZON PHARMAC. GRP H YC1 Cash Flow Quality Index
LIVZON PHARMAC. GRP H YC1 cash flow quality index. LIVZON PHARMAC. GRP H YC1 (LP6) has a Cash Flow Quality Index of 1.55x as of December 2025. Operating cash flow of €3.15 Billion exceeds net income of €2.02 Billion, indicating high earnings quality where cash backs reported profits. See LP6 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of LIVZON PHARMAC. GRP H YC1 (2021–2025)
Cash flow quality index of LIVZON PHARMAC. GRP H YC1 from 2021 to 2025. Historical Cash Flow Quality Index for LIVZON PHARMAC. GRP H YC1 across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore debt repayment capacity of LIVZON PHARMAC. GRP H YC1 to assess how comfortably operating cash covers total debt obligations.
LIVZON PHARMAC. GRP H YC1 Cash Flow Quality Index by Year (2021–2025)
LIVZON PHARMAC. GRP H YC1 cash flow quality index by year from 2021 to 2025. Year-by-year earnings quality comparison for LIVZON PHARMAC. GRP H YC1. For the full cash flow conversion analysis, see LP6 cash generation efficiency.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.55x | €3.15 Billion | €2.02 Billion | ▲ +7.6% |
| 2024 | 1.45x | €2.98 Billion | €2.06 Billion | ▼ -13.1% |
| 2023 | 1.66x | €3.25 Billion | €1.95 Billion | ▲ +14.5% |
| 2022 | 1.45x | €2.77 Billion | €1.91 Billion | ▲ +35.5% |
| 2021 | 1.07x | €1.90 Billion | €1.78 Billion | — |